Literature DB >> 1379133

Anti-myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase.

R J Falk1, M Becker, R Terrell, J C Jennette.   

Abstract

We wondered whether anti-myeloperoxidase (MPO) autoantibodies (MPO-ANCA) found in patients with systemic vasculitis react with a conformational epitope or epitopes on the MPO molecule. Sera from 15 human MPO-ANCA, and a polyclonal and a monoclonal anti-MPO antibodies were reacted with MPO in native and denatured states. Human MPO-ANCA and mouse monoclonal anti-MPO reacted with native MPO, and a 120-kD band representing the MPO hologenzyme, but not with denatured MPO fragments; however, MPO-ANCA and mouse anti-MPO did not demonstrate competitive inhibition of binding to MPO. Polyclonal rabbit anti-MPO reacted with both native and denatured MPO. All MPO-ANCA tested showed the same patterns of reactivity with native and denatured MPO in dot blot and Western blot analyses. Both polyclonal and monoclonal anti-MPO antibodies inhibited MPO's protein iodination by over 90%, whereas MPO-ANCA IgGs, normal IgGs and disease control IgGs did not. These data suggest that (i) MPO-ANCA interact with a conformational epitope on the MPO molecule; and (ii) MPO-ANCA from different patients have similar reactivity with native versus denatured MPO.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379133      PMCID: PMC1554440          DOI: 10.1111/j.1365-2249.1992.tb06944.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

Review 1.  ANCA-associated renal disease.

Authors:  R J Falk
Journal:  Kidney Int       Date:  1990-11       Impact factor: 10.612

2.  Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3.

Authors:  J C Jennette; J R Hoidal; R J Falk
Journal:  Blood       Date:  1990-06-01       Impact factor: 22.113

Review 3.  The antigenic structure of proteins: a reappraisal.

Authors:  D C Benjamin; J A Berzofsky; I J East; F R Gurd; C Hannum; S J Leach; E Margoliash; J G Michael; A Miller; E M Prager
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

4.  The reductive cleavage of myeloperoxidase in half, producing enzymically active hemi-myeloperoxidase.

Authors:  P C Andrews; N I Krinsky
Journal:  J Biol Chem       Date:  1981-05-10       Impact factor: 5.157

5.  Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.

Authors:  R J Falk; R S Terrell; L A Charles; J C Jennette
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

6.  Reactivity of anti-neutrophil cytoplasmic autoantibodies with HL-60 cells.

Authors:  L A Charles; R J Falk; J C Jennette
Journal:  Clin Immunol Immunopathol       Date:  1989-11

7.  Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis.

Authors:  B Nölle; U Specks; J Lüdemann; M S Rohrbach; R A DeRemee; W L Gross
Journal:  Ann Intern Med       Date:  1989-07-01       Impact factor: 25.391

8.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.

Authors:  R J Falk; J C Jennette
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

Review 9.  Antineutrophil cytoplasmic autoantibodies and associated diseases: a review.

Authors:  J C Jennette; R J Falk
Journal:  Am J Kidney Dis       Date:  1990-06       Impact factor: 8.860

10.  Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme.

Authors:  J Lüdemann; B Utecht; W L Gross
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

View more
  15 in total

Review 1.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Analysis of immunoglobulin variable region genes of a human IgM anti-myeloperoxidase antibody derived from a patient with vasculitis.

Authors:  C Longhurst; M R Ehrenstein; B Leaker; F K Stevenson; M Spellerberg; C Chapman; D Latchmen; D A Isenberg; G Cambridge
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

Review 3.  The diversity of perinuclear antineutrophil cytoplasmic antibodies (pANCA) antigens.

Authors:  A Wiik; L Stummann; L Kjeldsen; N Borregaard; S Ullman; S Jacobsen; P Halberg
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

4.  A comparison of the characteristics of circulating anti-myeloperoxidase autoantibodies in vasculitis with those in non-vasculitic conditions.

Authors:  I C Locke; B Leaker; G Cambridge
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

Review 5.  Neutrophil functions of patients with vasculitis related to myeloperoxidase-specific anti-neutrophil antibody.

Authors:  K Suzuki
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

Review 6.  B cell epitope specificity in ANCA-associated vasculitis: does it matter?

Authors:  Y M van der Geld; C A Stegeman; C G M Kallenberg
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

7.  Epitope mapping of anti-proteinase 3 and anti-myeloperoxidase antibodies.

Authors:  L Chang; S Binos; J Savige
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

8.  Studies of epitope restriction on myeloperoxidase (MPO), an important antigen in systemic vasculitis.

Authors:  A K Short; C M Lockwood
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

9.  Anti-myeloperoxidase antibodies in sera from patients with propylthiouracil-induced vasculitis might recognize restricted epitopes on myeloperoxidase molecule.

Authors:  H Ye; M-H Zhao; Y Gao; X-H Guo; H-Y Wang
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

10.  Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates, and IgG subclass.

Authors:  G Cambridge; M Williams; B Leaker; M Corbett; C R Smith
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.